We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Zol3.0
Zoledronate Research
Mostly mechanism / observational
102 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Zoledronate studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2007–2026 with a typical study size of 211 participants.
Based on 102 studies · 17 meta-analyses · 77 RCTs · 64,110 total participants
Confidence
High confidence
By outcome
Fracture & boneProven reduction in clinical and vertebral/hip fractures in osteoporosis · Years
Mostly mechanism / observational63 studies
Mortality & aging
Mostly mechanism / observational5 studies
Safety profile
Mostly mechanism / observational4 studies
Active research area
50 studies in the last 5 years · Latest meta-analysis: 2026
200720162026
1Meta-Analysis2021
Sun Y, Ma H, Yang F, Tang X, Yi P, Tan M · Biomed Res Int (2021)
In plain English: Level of evidence Level I, therapeutic study.
Lan Z, Lin X, Xue D, Yang Y, Saad M, Jin Q. · Clinical orthopaedics and related research (2025)
Due to the low heterogeneity among the studies, as evidenced by the low statistical heterogeneity (that is, a low I 2 statistic), we opted for a fixed-effects model, indicating that the effect size is consistent across the studies.
Results The use of bisphosphonates did not reduce the overall risk of mortality in patients with osteoporosis (risk ratio 0.95 [95% CI 0.88 to 1.03]).
Conclusion Based on our comprehensive meta-analysis, there is high-quality evidence suggesting that bisphosphonate therapy for patients with osteoporosis does not reduce the overall risk of mortality despite its effectiveness in reducing the risk of fractures.
In plain English: Conclusions Ten years after trial initiation, zoledronate administered at baseline and 5 years was effective in preventing morphometric vertebral fracture in early postmenopausal women. (Funded by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12612000270819.).
Bolland MJ, Nisa Z, Mellar A, Gasteiger C, Pinel V, Mihov B, Bastin S, Grey A, Reid IR, Gamble G, Horne A. · The New England journal of medicine (2025)
The primary end point was morphometric vertebral fracture, which was assessed semiquantitatively and defined as at least a 20% change in vertebral height from that seen on the baseline radiograph.
Results Of 1054 women with a mean age of 56.0 years at baseline, 1003 (95.2%) completed 10 years of follow-up.